Unimolecular dual-agonists targeting the receptors for GLP-1 and GIP decrease body weight and improve glucose handling in animal models of obesity and T2DM (Coskun et al., 2018; Finan et al., 2013), non-human primates (Finan et al., 2013), and obese patients with T2DM (Coskun et al., 2018; Finan et al., 2013; Frias et al., 2018). The gene discussed is GIP; the disease is type 2 diabetes mellitus.